title: Clinical and biological characteristics of familial benign prostatic hyperplasia.
abstract: OBJECTIVE
  We attempted to determine the clinical and biological characteristics of familial benign prostatic hyperplasia (BPH).
  
  
  METHODS
  Urinary flow rate, prostate size, symptom score, serum prostate specific antigen, testosterone and dihydrotestosterone were measured in subjects who participated in the nationwide Merck phase III finasteride clinical trial. Findings in the 69 men with familial BPH (3 or more family members with BPH, including the proband) were compared to those in the 345 with no family history of BPH. Logistic regression was used to detect relationships between familial BPH, and these variables before and after 5 alpha-reductase inhibition with finasteride.
  
  
  RESULTS
  Familial BPH was characterized by large prostate size. Mean prostate volume in men with familial and sporadic BPH was 82.7 and 55.5 ml., respectively (p < 0.001). Other clinical findings, including serum androgen levels and response to finasteride, were similar in familial and sporadic BPH. The frequency of familial BPH in patients with prostate size in the largest and smallest deciles was 46 and 13%, respectively.
  
  
  CONCLUSIONS
  Familial BPH in this group of patients was associated with large prostate size, normal serum androgen levels and normal response to 5 alpha-reductase inhibition. A genetic factor responsible for familial BPH may exert its influence through androgen independent control of prostatic growth.
authors.affiliation: Urology Section, University of Michigan, Ann Arbor, USA.
authors.forename: M G
authors.initials: MG
authors.lastname: Sanda
authors.forename: C B
authors.initials: CB
authors.lastname: Doehring
authors.forename: B
authors.initials: B
authors.lastname: Binkowitz
authors.forename: T H
authors.initials: TH
authors.lastname: Beaty
authors.forename: A W
authors.initials: AW
authors.lastname: Partin
authors.forename: E
authors.initials: E
authors.lastname: Hale
authors.forename: E
authors.initials: E
authors.lastname: Stoner
authors.forename: P C
authors.initials: PC
authors.lastname: Walsh
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000368:Aged; D017326:Clinical Trials, Phase III as Topic; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
chemical_list: D058891:5-alpha Reductase Inhibitors; D018120:Finasteride; D017430:Prostate-Specific Antigen